Advertisement

Topics

Biogen Builds on Its 40-Year Legacy in Neuroscience with Presentation of Research from Its Portfolio of Medicines and Investigational Programs for Neurodegenerative Diseases

07:30 EDT 17 Apr 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
New data underscore benefits of SPINRAZA® (nusinersen) across broad spinal muscular atrophy (SMA) populations and include longer-term efficacy and safety assessments from the SHINE study Dat...

Other Sources for this Article

Biogen
MEDIA CONTACT:
David Caouette, +1 617-679-4945
public.affairs@biogen.com
or
INVESTOR CONTACT:
Matt Calistri, +1 781-464-2442
IR@biogen.com

NEXT ARTICLE

More From BioPortfolio on "Biogen Builds on Its 40-Year Legacy in Neuroscience with Presentation of Research from Its Portfolio of Medicines and Investigational Programs for Neurodegenerative Diseases"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...